Designing and Analyzing Clinical Trials for Personalized Medicine (DACTPerM)
In medical research, the treatment paradigm is shifting toward personalized medicine, where the goal is to match patients to the treatments most likely to deliver benefit. Treatment effects in various subpopulations may provide some information about treatment effects in other subpopulations. This working group will develop methodology and best practice guidelines for clinical trial design where treatments are being investigated or tested in several groups of patients.
Key Deliverable: Working Group will produce and disseminate a white paper that will serve as guidelines for designing and analyzing clinical trials for personalized medicine and testing heterogeneity of treatment effects.
Leadership
| Name (CTSA HUB) |
Role |
| Byron J Gajewski (Kansas) |
Co-Lead |
| Matthew S Mayo (Kansas) |
Co-Lead |
Membership
| Last Name |
First Name |
CTSA Hub |
| Bagiella |
Emilia |
Mount Sinai |
| Barohn |
Richard |
University of Kansas Medical Center |
| Berry |
Scott |
Berry Consultants/KUMC |
| Chen |
Zhengjia |
Emory |
| Dzomba |
Bari |
Penn State |
| Fontanesi |
John |
UCSD |
| Gajewski |
Byron |
University of Kansas Medical Center |
| Jennings |
Kristofer |
University of Texas Medical Branch |
| Karanevich |
Alex |
University of Kansas Medical Center |
| Lai |
Wei |
The Ohio State University |
| Long |
Qi |
Emory |
| Mayo |
Matthew |
University of Kansas Medical Center |
| Mermelstein |
Robin |
University of Illinois at Chicago |
| Messinger |
Shari |
Miami |
| Pollock |
Brad |
University of California, Davis |
| Rickey |
Carter |
Mayo |
| Selker |
Harry |
Tufts |
| Tardiff |
Barbara |
Pfizer, Inc. |
| Torner |
Jim |
University of Iowa |
| Zend |
Donglin |
University of North Carolina at Chapel Hill |
Meeting Schedule
4th Wednesday of each month, 2-3pm ET
Contact
methods_processes@ctsac4.org
